Myasthenia gravis nursing: complete reference guide

Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder in which antibodies block, destroy, or functionally impair acetylcholine receptors at the postsynaptic neuromuscular junction. The result is fluctuating, fatigable skeletal muscle weakness that worsens with activity and improves with rest — a hallmark pattern found nowhere else in neurology. MG affects approximately 20 per 100,000 people in the United States and is the most common primary disorder of the neuromuscular junction. It can present at any age, with a bimodal distribution: younger women (20s–30s) and older men (60s–70s). For NCLEX, MG is high-yield because it tests crisis differentiation (myasthenic versus cholinergic), medication timing, respiratory monitoring, and the recognition of drugs that worsen the disease. This reference covers all of it in full.

Myasthenia gravis quick-reference summary

Pathophysiology: why the NMJ fails

Myasthenia gravis is a disorder of neuromuscular transmission. Under normal conditions, action potentials traveling down a motor neuron trigger acetylcholine (ACh) release from presynaptic vesicles into the synaptic cleft. ACh binds to nicotinic receptors on the postsynaptic (muscle) membrane, generating an end-plate potential that initiates muscle contraction.

In MG, the immune system produces autoantibodies that target the postsynaptic NMJ:

Anti-AChR antibodies are present in approximately 85% of patients with generalized MG. These antibodies cause receptor dysfunction through three mechanisms: (1) blocking ACh binding directly, (2) activating complement-mediated destruction of the postsynaptic membrane, and (3) accelerating AChR internalization and degradation. The cumulative result is a reduced end-plate potential that falls below the threshold needed for muscle contraction — and because the available receptors are already compromised, repeated nerve firing further depletes the pool of functional receptors, producing the characteristic fatigability with activity.

Anti-MuSK antibodies (muscle-specific kinase) account for roughly 40–50% of the seronegative population (patients without anti-AChR antibodies), equivalent to about 10% of all MG cases overall. MuSK is a receptor tyrosine kinase essential for AChR clustering during NMJ development. Anti-MuSK MG tends to preferentially involve facial, oropharyngeal, and respiratory muscles; pyridostigmine is often less effective in this subgroup, and immunosuppression is typically first-line.

Anti-LRP4 antibodies are identified in a small subset of the remaining double-seronegative patients. LRP4 (low-density lipoprotein receptor-related protein 4) is the co-receptor that activates MuSK signaling.

The thymus in MG

The thymus gland plays a central role in MG pathogenesis. Approximately 70% of anti-AChR-positive patients have thymic hyperplasia (germinal center formation within the thymus), which is thought to drive ongoing autoantibody production. An additional 10–15% of MG patients have a thymoma — a thymic epithelial tumor that can be benign or malignant. Every patient with newly diagnosed generalized MG should receive a CT scan of the chest to screen for thymoma, because thymoma-associated MG tends to be more severe and warrants surgical removal (thymectomy) regardless of tumor size. Thymectomy also benefits patients with generalized anti-AChR-positive MG who are younger than 65, even in the absence of thymoma — the MGTX trial (2016, NEJM) demonstrated improved outcomes compared with immunosuppression alone.

Clinical presentation

MG weakness has a distinctive pattern: fatigable, fluctuating, and proximal-predominant. It worsens with sustained or repeated activity and improves with rest. This fatigability pattern is the single most important clinical feature for distinguishing MG from other causes of muscle weakness.

Ocular and bulbar involvement (most common onset)

• Ptosis (drooping of one or both eyelids) — present in over 50% of patients at onset; the eyelid droops progressively with sustained upward gaze
• Diplopia (double vision) — due to weakness of extraocular muscles; often the first symptom
• Dysphagia (difficulty swallowing) — predisposes to aspiration; saliva, liquids, and thin foods are highest risk
• Dysarthria (slurred speech) — often described as a nasal quality; worsens during prolonged talking
• Facial weakness — difficulty chewing; “MG sneer” (transverse smile) from zygomaticus weakness

Approximately 15% of patients have purely ocular MG (ocular MG) that never generalizes. The remainder develop generalized MG within 2–3 years of ocular onset if inadequately treated.

Limb and respiratory weakness

• Proximal limb weakness — difficulty rising from a chair, climbing stairs, raising arms above the head; distal weakness is unusual and should prompt reconsideration of the diagnosis
• Neck flexor weakness — inability to lift head off a pillow; “dropped head” syndrome in severe cases
• Respiratory muscle involvement — diaphragm and intercostal muscle weakness can rapidly progress to respiratory failure; this defines myasthenic crisis

Aggravating factors

Certain situations reliably worsen MG symptoms: heat, infection, stress, surgery, pregnancy (first trimester and postpartum), and a long list of medications that impair NMJ transmission (see Contraindicated drugs section). The worsening is physiological — at higher temperatures, acetylcholinesterase activity increases and the NMJ safety margin decreases further.

Myasthenic crisis vs. cholinergic crisis

This is the most tested MG concept on NCLEX and the most dangerous clinical situation you will encounter. Both crises cause respiratory failure — the difference is the mechanism and the treatment, which are opposite.

The SLUDGE / DUMBELS mnemonic for cholinergic crisis

When ACh overaccumulates at muscarinic receptors, it produces the SLUDGE syndrome:

• S — Salivation (excessive)
• L — Lacrimation (tearing)
• U — Urination (incontinence)
• D — Defecation (diarrhea, fecal incontinence)
• G — GI cramping
• E — Emesis (vomiting)

The DUMBELS mnemonic covers additional muscarinic signs: Defecation/Diarrhea, Urination, Miosis, Bradycardia/Bronchospasm/Bronchorrhea, Emesis, Lacrimation, Salivation.

At nicotinic receptors, ACh overload causes fasciculations followed by a depolarizing block and flaccid paralysis — the same mechanism as succinylcholine.

The Tensilon (edrophonium) test

Edrophonium is an ultrashort-acting acetylcholinesterase inhibitor (effect lasts 5–10 minutes) used to differentiate the two crises and to confirm MG diagnosis:

• In myasthenic crisis: edrophonium transiently increases available ACh → muscle strength visibly improves (positive test) → patient has too little ACh
• In cholinergic crisis: edrophonium adds more ACh to an already-overloaded system → weakness stays the same or worsens + SLUDGE symptoms increase → patient has too much ACh
• Atropine must be at the bedside during Tensilon testing because edrophonium can itself cause muscarinic toxicity (bradycardia, bronchospasm)
• The test is becoming less common in practice because it requires careful interpretation and carries procedural risk; anti-AChR antibody titers and repetitive nerve stimulation are preferred for initial diagnosis

Clinical rule for NCLEX

If your MG patient is in respiratory distress:

1. Assess for SLUDGE symptoms → present = cholinergic, absent = myasthenic
2. Check pupil size → miosis = cholinergic, normal/dilated = myasthenic
3. Check heart rate → bradycardia = cholinergic
4. When in doubt, do not give more pyridostigmine until the crisis type is identified — if it’s cholinergic, you will make the patient worse

Diagnosis

No single test confirms MG — diagnosis combines clinical assessment, antibody testing, and electrodiagnostic studies.

Serological testing

• Anti-AChR antibodies: Positive in approximately 85% of generalized MG and 50% of purely ocular MG. A positive result is nearly diagnostic (very high specificity). A negative result does not rule out MG.
• Anti-MuSK antibodies: Positive in approximately 40–50% of anti-AChR-negative patients. Important to test in seronegative cases because anti-MuSK MG requires a different management approach.
• Anti-LRP4 antibodies: Available at specialized centers for the remaining double-seronegative patients.

Bedside ice pack test

A simple, safe test for ptosis at the bedside. Place a bag of ice over the closed eye for 2 minutes, then assess ptosis. In MG, the cold reduces acetylcholinesterase activity → more ACh available → ptosis improves by ≥2 mm. Sensitivity approximately 80% for ocular MG. This test is used when the Tensilon test is not available or contraindicated.

Edrophonium (Tensilon) test

As described above — brief improvement in ptosis or diplopia after IV edrophonium injection confirms MG. Sensitivity ~80–90%. Atropine must be available; the test is contraindicated in patients with cardiac arrhythmias.

Electrodiagnostic studies

• Repetitive nerve stimulation (RNS): The NMJ is stressed by delivering repetitive electrical stimuli (3 Hz) to a peripheral nerve. In MG, successive stimuli lead to progressively diminishing muscle action potential amplitudes — a decremental response of ≥10% is abnormal and consistent with NMJ disorder. Sensitivity ~50–70% for generalized MG.
• Single-fiber electromyography (SF-EMG): The most sensitive test for MG (~95%). It measures the variability in timing between two adjacent muscle fibers in the same motor unit (“jitter”). Increased jitter indicates NMJ instability. A normal SF-EMG in a weak limb essentially rules out MG.

CT chest

Every newly diagnosed MG patient should have a CT scan of the chest to screen for thymoma. Thymoma can be benign or malignant and requires surgical removal. MRI of the chest is an alternative if CT is contraindicated.

Nursing assessment

Respiratory function — the priority assessment

Respiratory failure is the most dangerous MG complication. Assess continuously in any acutely ill MG patient:

• Forced vital capacity (FVC): The single most important parameter. Normal is 60–70 mL/kg. Intubation is generally indicated when FVC falls below 15–20 mL/kg (approximately 1 L in an average adult). Trends matter more than single values — a falling FVC in an MG patient is a medical emergency.
• Accessory muscle use: Neck, sternocleidomastoid, and intercostal muscle recruitment signals impending failure
• Speaking quality: Ask the patient to count to 20 aloud — a voice that fades or becomes increasingly nasal during counting indicates bulbar fatigue
• Swallow assessment: Ask the patient to swallow a small sip of water. Coughing, choking, or a wet voice after swallowing indicates significant dysphagia and aspiration risk
• Single-breath count: Ask the patient to take a deep breath and count aloud as long as possible on a single breath. Fewer than 20 indicates significantly reduced respiratory reserve.
• SpO2 and respiratory rate: Late findings — do not wait for desaturation to act in MG

Functional and ocular assessment

• Document ptosis (unilateral vs. bilateral, worsening with sustained upward gaze)
• Assess diplopia — which directions of gaze are affected
• Test facial muscle strength (can the patient smile symmetrically, close eyes against resistance)
• Assess time-of-day variation — weakness at its worst in the afternoon and evening, best in the morning after rest

Fatigue timing and activity tolerance

Ask patients to rate their symptoms at different times of day. Most MG patients have a predictable diurnal pattern: best in the morning, worst in the afternoon and after exertion. Document this pattern — it drives medication timing and activity scheduling.

Crisis risk assessment

Identify patients at elevated risk for crisis:

• Recent infection or illness
• New medication added that can worsen MG (see contraindicated drugs)
• Recent surgery or general anesthesia
• Increasing pyridostigmine dose without improvement (may indicate cholinergic overmedication)
• New or worsening dysphagia (bulbar involvement increases aspiration and respiratory risk)

Nursing interventions

Medication timing — critical for aspiration prevention

Pyridostigmine must be given 30 minutes before meals. Dysphagia peaks when drug levels are low; administering pyridostigmine before eating allows peak drug effect to coincide with the swallowing effort of the meal. Giving it with or after food means the patient is eating at drug trough — the highest-risk period for aspiration. This timing principle is one of the most frequently tested NCLEX points for MG.

Do not crush extended-release pyridostigmine (Mestinon Timespan) — the extended-release formulation must remain intact to deliver the controlled release profile.

Aspiration precautions

• Upright position (HOB ≥ 30°, preferably 45–90°) during all oral intake
• Offer foods at the time of peak drug effect — mid-morning for most patients
• Provide soft, cohesive foods; avoid thin liquids if swallow assessment is abnormal (thickened liquids as ordered)
• Speech-language pathology referral for formal swallow evaluation
• Suction equipment and emergency airway supplies at bedside in hospitalized patients
• NPO if aspiration risk is high; nasogastric or PEG tube feeding as needed

Activity pacing

• Schedule all essential activities (bathing, physical therapy, meals) in the morning when the patient is strongest
• Teach the patient to rest before activities that require sustained exertion
• Avoid heat — hot showers, hot weather, and fever all worsen symptoms by increasing acetylcholinesterase activity and reducing the NMJ safety margin
• Eye patching (alternating eyes) can temporarily relieve diplopia

Respiratory monitoring and crisis preparation

• Perform serial FVC measurements in any hospitalized MG patient — not just spot checks
• Have rapid response criteria agreed upon in advance: FVC < 20 mL/kg, SpO2 < 92%, worsening accessory muscle use, inability to speak in full sentences
• Ensure noninvasive ventilation (BiPAP) and intubation equipment are available
• Know your facility’s crisis protocol — who to call and when
• IVIG and plasmapheresis are the two crisis treatments; expect a 1–3 day lag before clinical improvement with either modality

Patient education

• Recognize early crisis signs: increasing weakness, voice changes, difficulty swallowing, shortness of breath
• Medication adherence: never skip pyridostigmine doses and never take more than prescribed without provider guidance
• Carry a medical alert identification (MG crisis and drug sensitivities)
• Avoid known triggers: extreme heat, overexertion, infections (get vaccinated — influenza, pneumococcal)
• Disclose MG diagnosis to every provider before any medication is prescribed or surgery is considered
• Reproductive counseling: MG is managed carefully in pregnancy; neonatal MG can occur from transplacental antibody transfer and resolves within weeks

Pharmacology

Contraindicated drugs in MG

This list is high-yield because administering a contraindicated drug can precipitate myasthenic crisis in a stable patient. Every provider involved in a patient’s care must be alerted to the diagnosis.

Drugs that worsen NMJ transmission and are contraindicated or used with extreme caution in MG:

• Aminoglycosides (gentamicin, tobramycin, amikacin) — impair presynaptic ACh release and reduce postsynaptic sensitivity; one of the most dangerous drug classes in MG
• Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) — can precipitate acute MG exacerbation; avoid if alternative antibiotics are available
• Beta-blockers (propranolol, metoprolol, atenolol) — impair neuromuscular transmission; use with caution; non-selective beta-blockers are worse
• Calcium channel blockers — can worsen NMJ transmission by reducing calcium-dependent ACh vesicle release
• Magnesium sulfate — reduces presynaptic ACh release; particularly dangerous because it is commonly given in obstetric emergencies (eclampsia) — MG nurses must flag this
• Neuromuscular blocking agents (succinylcholine, vecuronium, rocuronium) — dramatically prolonged blockade in MG; avoid if possible; if required (surgery), inform anesthesia of diagnosis
• Chloroquine and hydroxychloroquine — can worsen NMJ transmission; notable because hydroxychloroquine is used in other autoimmune diseases
• Quinine / quinidine — reduce ACh release; quinine found in tonic water in high quantities should be avoided
• D-penicillamine — can actually induce MG de novo in patients being treated for rheumatoid arthritis
• Procainamide, quinidine — antiarrhythmics with NMJ-blocking properties

Mnemonic for flagging antibiotic classes: Aminoglycosides and Fluoroquinolones are the Absolute Flag — think “AF in MG = Avoid Forever.”

Crisis management

When to escalate

Call rapid response or transfer to ICU-level care when:

• FVC falls below 20 mL/kg (approximately 1 L)
• SpO2 < 92% or rapid desaturation trend
• Patient unable to speak in full sentences due to respiratory fatigue
• Accessory muscle use is worsening despite positioning and supplemental oxygen
• Patient cannot manage secretions (drooling, unable to swallow)

Intubation considerations

MG patients may require intubation for airway protection and ventilatory support. Communicate the diagnosis to anesthesia and critical care immediately:

• Neuromuscular blocking agents have prolonged effects in MG — succinylcholine dose requirements may be higher (resistance due to reduced AChR availability), while non-depolarizing agents are markedly potentiated (use smaller doses)
• Avoid aminoglycosides perioperatively
• Plan for extended weaning — extubation failure is common and may require multiple attempts

IVIG vs. plasmapheresis for crisis

Both are effective:

• Plasmapheresis acts faster (improvement in 24–48 hours) and is preferred when the fastest possible response is needed
• IVIG is easier to administer (no central line required for peripheral IVIG), onset 3–5 days
• Both provide short-term benefit lasting 3–6 weeks — long-term immunosuppression must be optimized concurrently
• Choice depends on venous access, patient comorbidities, and institutional resources

Cholinergic crisis management

1. Stop all anticholinesterase medications immediately
2. Administer atropine IV for bronchospasm, bradycardia, or excessive secretions
3. Support ventilation (noninvasive or mechanical as needed)
4. Monitor and treat electrolyte disturbances
5. Once the patient is stabilized, restart anticholinesterase at a lower dose after 48–72 hours

Complications

10 NCLEX tips for myasthenia gravis

1. Crisis differentiation is everything. Myasthenic crisis = too little ACh (undertreated) → Tensilon improves → increase anticholinesterase. Cholinergic crisis = too much ACh (overmedicated) → SLUDGE symptoms → STOP anticholinesterase + give atropine. Both cause respiratory failure. This is the #1 MG NCLEX differentiator.

2. Pyridostigmine timing: 30 minutes before meals. Never after. The reason is aspiration prevention — the drug must reach peak effect before the patient swallows food. A question describing a nurse giving pyridostigmine with meals is describing an error.

3. Respiratory monitoring is the priority assessment. FVC is the key measure. When FVC falls below 15–20 mL/kg, intubation is needed. SpO2 is a late finding — do not wait for desaturation. A worsening voice (count-to-20 test) or increasing accessory muscle use are early warning signs.

4. Atropine must be at the bedside during Tensilon testing. Edrophonium can cause bradycardia and bronchospasm. This is a classic safety question. If a test question asks what the nurse prepares before a Tensilon test, atropine is the correct answer.

5. MG weakness worsens with activity and improves with rest. This is the cardinal clinical feature. It is the opposite of most other muscle diseases. If a NCLEX question describes weakness that gets better after the patient rests, think MG first.

6. Aminoglycosides and fluoroquinolones are contraindicated. These antibiotic classes impair NMJ transmission and can precipitate myasthenic crisis. A question asking which antibiotic to avoid in MG has one of these as the correct answer.

7. Magnesium sulfate is dangerous in MG. It reduces presynaptic ACh release. This is especially important in postpartum patients who may receive MgSO4 for eclampsia prevention — flag the MG diagnosis to obstetric providers.

8. Thymectomy benefits generalized anti-AChR-positive MG patients under 65, even without thymoma. Every MG patient needs a CT chest at diagnosis. Thymoma does not always mean cancer, but it must be removed.

9. Heat worsens MG. Advise patients to avoid hot showers, saunas, hot weather, and fever-inducing illness. Cold (ice pack test) improves function — that is why the ice pack test works.

10. Prednisone can transiently worsen MG in the first 1–3 weeks. The mechanism is not fully understood but may relate to direct effects on the NMJ. Patients should be warned and may need hospitalization during steroid initiation if their baseline is fragile.

Related nursing references

Myasthenia gravis sits within the broader neurological cluster of content you need for NCLEX. These reference pages cover related conditions and skills:

• ALS nursing reference — another motor neuron disease with respiratory failure as the primary complication; compare the UMN/LMN picture with MG’s pure NMJ pathology
• Multiple sclerosis nursing reference — demyelinating disease with relapsing-remitting course; contrasts with MG’s fatigability pattern and autoimmune NMJ mechanism
• Parkinson’s disease nursing reference — covers dopamine deficiency and movement disorders; useful for comparing neurotransmitter-based pathologies
• Alzheimer’s disease nursing reference — neurodegenerative disease with cholinergic deficit; contrast with MG where the issue is ACh receptor availability, not production
• Seizure nursing reference — another high-yield neurological emergency; both MG and seizure patients require rapid respiratory assessment and airway management
• Glasgow coma scale — essential neurological assessment tool for any patient in acute crisis, including myasthenic or cholinergic crisis with altered level of consciousness
• Drug classifications guide — acetylcholinesterase inhibitors, immunosuppressants, and complement inhibitors all appear in MG pharmacology; this reference covers drug class mechanisms and nursing considerations across all categories